Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular Pathogenesis of MDS.

A Thomas Look1

  • 1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115-6084, USA. thomas_look@dfci.harvard.edu

Hematology. American Society of Hematology. Education Program
|November 24, 2005
PubMed
Summary

Myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD) involve clonal chromosomal deletions that inactivate crucial tumor suppressor genes. Identifying these genes is key to understanding myeloid development and advancing MDS treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reactivation of a TAL1 progenitor cell enhancer region by non-coding somatic variants in T-lineage acute lymphoblastic leukemia.

bioRxiv : the preprint server for biology·2026
Same author

Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation.

Cell reports·2026
Same author

Multitargeted Reduction of Inflammation and Atherosclerosis in <i>Tet2</i> -deficient CHIP via XPO1 Inhibition and Atf3 restoration.

bioRxiv : the preprint server for biology·2025
Same author

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma.

bioRxiv : the preprint server for biology·2025
Same author

Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation.

Cell reports·2025
Same author

Accurate Measurement of Cell Number-Normalized Differential Gene Expression in Cells Treated With Retinoic Acid.

Bio-protocol·2024

Area of Science:

  • Hematology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Clonal hematopoietic stem and progenitor cell disorders, including myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD), significantly impact both pediatric and adult patients.
  • These diseases are characterized by clonal, nonrandom chromosomal deletions (e.g., 7q-, 5q-) that inactivate tumor suppressor genes essential for normal myeloid cell development.
  • Identifying these tumor suppressors is challenging due to large deleted regions and the unclear role of haploinsufficiency versus homozygous inactivation.

Purpose of the Study:

  • To investigate the role of inactivated tumor suppressor genes in the pathogenesis of MDS and MPD.
  • To understand the molecular mechanisms underlying dysfunctional myelopoiesis caused by chromosomal deletions.
  • To identify critical genes lost through deletions that contribute to MDS and MPD.

Related Experiment Videos

Main Methods:

  • Analysis of chromosomal deletions in MDS and MPD patient samples.
  • Review of existing literature on genetic features and identified mutations in myeloid diseases.
  • Comparative analysis of large deleted regions to pinpoint candidate tumor suppressor genes.

Main Results:

  • Chromosomal deletions, such as 7q- and 5q-, are common in MDS and MPD, suggesting the inactivation of tumor suppressor genes.
  • While some mutations in known hematopoietic genes (e.g., RUNX1, PU.1) have been identified, most deletion-associated tumor suppressors remain elusive.
  • The precise mechanism of myelopoiesis dysfunction (haploinsufficiency vs. homozygous inactivation) requires further clarification.

Conclusions:

  • Understanding the molecular basis of MDS and MPD, particularly the function of lost tumor suppressor genes, is critical for developing targeted therapies.
  • Advances in MDS treatment are contingent upon a comprehensive understanding of the underlying genetic alterations and their impact on myeloid development.
  • Further research is needed to identify the specific tumor suppressor genes affected by chromosomal deletions in these clonal hematopoietic disorders.